Eli Lilly and Company (LLY)
| Market Cap | 731.71B |
| Revenue (ttm) | 35.93B |
| Net Income (ttm) | 6.14B |
| Shares Out | 950.41M |
| EPS (ttm) | 6.79 |
| PE Ratio | 113.40 |
| Forward PE | 57.22 |
| Dividend | $5.20 (0.68%) |
| Ex-Dividend Date | May 15, 2024 |
| Volume | 1,041,553 |
| Open | 772.89 |
| Previous Close | 771.12 |
| Day's Range | 767.10 - 774.87 |
| 52-Week Range | 419.80 - 800.78 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 755.50 (-1.88%) |
| Earnings Date | Apr 30, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
Financial Performance
In 2023, LLY's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $755.5, which is a decrease of -1.88% from the latest price.
News
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly
Collaboration leverages Totus' covalent chemistry-based OmniDEL platform for the identification of small molecule drug candidates across multiple therapeutic areas Collaboration leverages Totus' coval...
Lilly's weekly insulin succeeds in late-stage studies
Eli Lilly said on Thursday that its once-weekly insulin efsitora met the main goals in two late-stage trials evaluating it in people with type 2 diabetes.
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes Efsitora was equally safe and effective among adults naïve to insul...
Bullish On TOST & LLY
Should traders remain bullish with the current macro environment? Tom Plumb says that a good sustainable business plan, good people, disciplined allocation of capital, high return on capital, and prof...
How Are Eli Lilly's Profit Margins Trending?
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development expenses (I...
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down
Britain's Pharmacy2U said on Wednesday it had cut the prices of weight-loss medication Wegovy and Mounjaro, becoming the latest in a slew of online pharmacies and slimming clinics to do so as initial ...
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
INDIANAPOLIS , May 15, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance ...
Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member
STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer...
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs
Eli Lilly has entered into a settlement deal with a medi spa that had sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, the drugmaker said on Tuesday.
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says
A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind's new AI model can predict the structure of molecules.
Is Eli Lilly Stock A Better Pick Over Amgen?
Given its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ NASDAQ : AMGN). Both stocks have been in the limelight lately, given their focus on the luc...
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart monitoring tech was approved for use in clinical studies.
US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10
Eli Lilly said on Tuesday a panel of independent U.S. FDA advisers will discuss whether the agency should approve its Alzheimer's disease drug, donanemab, on June 10.
Lilly Declares Second-Quarter 2024 Dividend
INDIANAPOLIS , May 6, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common s...
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.
Wegovy, Mounjaro prices cut as British pharmacies compete for weight-loss patients
Online pharmacies and slimming clinics are cutting prices for Wegovy and Mounjaro in Britain just months after the weight-loss drugs were launched there, as initial supply shortages ease.
Trade Tracker: Joe Terranova sells Eli Lilly
The Investment Committee discusses the healthcare sector as Joe Terranova sells Eli Lilly in his JOET rebalance.
Potential for Weight-Loss Drugs Boosts Eli Lilly
Eli Lilly & Co.'s shares soared as its brighter outlook for 2024 raised the potential ceiling for new weight-loss drugs even further in the eyes of analysts and investors. Lilly says supply and pricin...
Eli Lilly stock soars on earnings, 'off-the-charts' demand for weight-loss drugs
Shares of Eli Lilly (LLY) are soaring in Tuesday's trading session after the company raised its full-year guidance, driven by the surging demand for its offerings. BMO Capital Markets BioPharma Equity...
Eli Lilly Leaps After Earnings
Biopharmaceutical giant Eli Lilly raised full-year guidance after reporting a 26% year-over-year revenue rise in its 1st quarter. Led by sales of obesity & diabetes drugs, Eli Lilly's chart has flirte...
Eli Lilly Stock Surges on Demand for Weight-Loss Drugs
Eli Lilly beat earnings expectations for the first quarter and raised its outlook for the year.
Eli Lilly (LLY) stock soars, Q1 earnings results show 26% revenue growth
The Eli Lilly And Company (NYSE: LLY) stock has jumped +53.33 (7.23%) after the company reported strong financial performance in its Q1 earnings report. At press time, the Eli Lilly stock was trading ...
Eli Lilly Stock Surges as Weight Loss Drugs Continue to Fuel Growth
Eli Lilly (LLY) stock jumped in early trading Tuesday after the drugmaker reported first-quarter earnings that beat analysts' expectations and raised its guidance thanks to continued high demand for t...
Eli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise Chen
Louise Chen, Cantor Fitzgerald managing director, joins 'Squawk Box' to discuss Eli Lilly's quarterly earnings results, weight loss drug demand, growth outlook, and more.